ATE156859T1 - Varianten von pai-2 - Google Patents

Varianten von pai-2

Info

Publication number
ATE156859T1
ATE156859T1 AT91901253T AT91901253T ATE156859T1 AT E156859 T1 ATE156859 T1 AT E156859T1 AT 91901253 T AT91901253 T AT 91901253T AT 91901253 T AT91901253 T AT 91901253T AT E156859 T1 ATE156859 T1 AT E156859T1
Authority
AT
Austria
Prior art keywords
variants
pai
pct
sec
compositions
Prior art date
Application number
AT91901253T
Other languages
English (en)
Inventor
Neil Howard Goss
Michael Andrew Richardson
Original Assignee
Biotech Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotech Australia Pty Ltd filed Critical Biotech Australia Pty Ltd
Application granted granted Critical
Publication of ATE156859T1 publication Critical patent/ATE156859T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121Serpins
    • C07K14/8132Plasminogen activator inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91901253T 1989-12-20 1990-12-20 Varianten von pai-2 ATE156859T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPJ792489 1989-12-20

Publications (1)

Publication Number Publication Date
ATE156859T1 true ATE156859T1 (de) 1997-08-15

Family

ID=3774424

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91901253T ATE156859T1 (de) 1989-12-20 1990-12-20 Varianten von pai-2

Country Status (10)

Country Link
US (1) US5444153A (de)
EP (1) EP0458937B1 (de)
JP (1) JP2567536B2 (de)
AT (1) ATE156859T1 (de)
AU (1) AU625018B2 (de)
DE (1) DE69031271T2 (de)
DK (1) DK0458937T3 (de)
ES (1) ES2106772T3 (de)
GR (1) GR3025330T3 (de)
WO (1) WO1991009124A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346627B1 (en) 1990-02-01 2002-02-12 Emory University Intermediates in the synthesis of 1,3-oxathiolane nucleoside enantiomers
DE4214215A1 (de) * 1992-04-30 1993-11-04 Behringwerke Ag Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen
DE4214999C2 (de) * 1992-05-06 1994-07-14 Behringwerke Ag Reinigung von Plasminogen-Aktivator-Inhibitor 2 durch Immunaffinitätschromatographie
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
EA001920B1 (ru) 1997-03-19 2001-10-22 Эмори Юниверсити Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b
US5994309A (en) * 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
JP2002526382A (ja) 1998-04-01 2002-08-20 バイオテック・オーストラリア・ピーティーワイ・リミテッド 皮膚創傷の治療へのプロテアーゼ阻害剤の使用
AUPP508798A0 (en) * 1998-08-05 1998-08-27 Biotech Australia Pty Limited Method of treating psoriasis
EP1066834A3 (de) * 1999-07-08 2004-06-02 Thomas Dr. Stief Pharmazeutische Zusammensetzungen enthaltend ein phagozytenmodulierendes Agens
AUPQ380699A0 (en) * 1999-11-02 1999-11-25 Biotech Australia Pty Limited Protease inhibitors as modulators of periodontal wound healing
AUPQ582400A0 (en) * 2000-02-24 2000-03-16 Biotech Australia Pty Limited A method of treatment and agents for use therein
US8062637B2 (en) * 2000-05-08 2011-11-22 Morphosys Ag Methods of ameliorating inflammatory disease using an uPA antagonist
US7455836B2 (en) * 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
US6562572B1 (en) * 2000-09-27 2003-05-13 Mayo Foundation For Medical Education And Research Methods for amplifying nucleic acid sequences
EP2224949B1 (de) * 2007-11-30 2012-10-17 University of Debrecen Verwendung von Plasminogen-Aktivator-Inhibitoren vom Urokinase-Typ zur Behandlung von kornealen Erkrankungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923807A (en) * 1984-05-18 1990-05-08 New England Medical Center Hospitals Inc. Arg-Serpin human plasminogen activator inhibitor designated PAI-2
JPH0655152B2 (ja) * 1984-08-13 1994-07-27 バイオテクノロジー・オーストラリア・ピーテイーワイ・リミテツド ミナクチビンの製造方法
IL81879A (en) * 1986-03-13 1994-07-31 Biotech Australia Pty Ltd Purification of minactivin for homogeneity, production of minactivin as recombinant techniques, and uses of homogeneous or recombinant minactivin
AU608752B2 (en) * 1986-03-13 1991-04-18 Australian National University, The Minactivin produced by recombinant dna technology
DE3722673A1 (de) * 1987-04-18 1989-01-19 Behringwerke Ag Fuer plasminogenaktivator-inhibitor, typ 2 (pai-2) codierende dna
EP0446315B1 (de) * 1989-09-05 1997-06-11 Biotechnology Australia Pty. Ltd. Verfahren zur herstellung von pai-2

Also Published As

Publication number Publication date
DE69031271D1 (de) 1997-09-18
DK0458937T3 (da) 1998-02-23
WO1991009124A1 (en) 1991-06-27
US5444153A (en) 1995-08-22
AU6967191A (en) 1991-07-18
EP0458937A4 (en) 1992-04-01
ES2106772T3 (es) 1997-11-16
DE69031271T2 (de) 1998-02-26
AU625018B2 (en) 1992-06-25
GR3025330T3 (en) 1998-02-27
JP2567536B2 (ja) 1996-12-25
EP0458937B1 (de) 1997-08-13
EP0458937A1 (de) 1991-12-04
JPH04503761A (ja) 1992-07-09

Similar Documents

Publication Publication Date Title
DE69031271D1 (de) Varianten von pai-2
Tokunaga et al. The factor V-activating enzyme (RVV-V) from Russell's viper venom. Identification of isoproteins RVV-V alpha,-V beta, and-V gamma and their complete amino acid sequences.
Radcliffe et al. Activation and control of factor VII by activated factor X and thrombin. Isolation and characterization of a single chain form of factor VII
Netzel-Arnett et al. Sequence specificities of human fibroblast and neutrophil collagenases.
Vissers et al. Cleavage and inactivation of alpha 1-antitrypsin by metalloproteinases released from neutrophils.
DE69027024D1 (de) Matritzenmetalloproteinasepeptide, ihre wirkung in diagnose und therapie
Neves-Ferreira et al. Isolation and characterization of DM40 and DM43, two snake venom metalloproteinase inhibitors from Didelphis marsupialis serum
Glover et al. Synthetic peptide inhibitors of complement serine proteases—I. Identification of functionally equivalent protease inhibitor sequences in serpins and inhibition of C1s and D
ATE264913T1 (de) Protease-resistente analoge des thrombomodulin
Bradford et al. Contiguous binding and inhibitory sites on kininogens required for the inhibition of platelet calpain.
Sanchez et al. Structural and functional characterization of a P-III metalloproteinase, leucurolysin-B, from Bothrops leucurus venom
FR2861731B1 (fr) Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
de Agostini et al. A common neoepitope is created when the reactive center of C1-inhibitor is cleaved by plasma kallikrein, activated factor XII fragment, C1 esterase, or neutrophil elastase.
DE69132889D1 (de) Überlegende thrombomodulinanaloga zur pharmazeutischen verwendung
DK0446315T3 (da) Fremgangsmåde til fremstilling af PAI-2
Mole et al. Structural evidence that complement factor B constitutes a novel class of serine protease.
Elion et al. Proteolytic derivatives of thrombin
JPH02147954A (ja) ヒトの血清または血漿におけるオステオカルシンの決定法
Briet et al. Cleavage and activation of human prothrombin by Echiscarinatus venom
Norman Effect of urea and methylamine on plasmin.
Heins et al. Kinetic investigation of the hydrolysis of aminoacyl p-nitroanilides by dipeptidyl peptidase IV from human and pig kidney
Samama et al. Crystallization and preliminary crystallographic data for bovine antithrombin III
Gramse et al. Degradation of human fibrinogen by chymotrypsin-like neutral protease from human granulocytes
Heinle et al. The binding of Evans blue to collagen and elastin in elastic tissue
Davies et al. Evidence that kidney lysosomal proteinases degrade the collagen of glomerular basement membrane

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee